WALTHAM, MA: Biotech company OxiGene, which is exploring therapies to treat cancer and eye disease, has hired Waggener Edstrom as AOR to tell its story to the public.
OxiGene's lead compound, CA4P, is currently entering phase 2 clinical trials, and might one day be used to treat advanced ovarian and lung cancers as well as age-related macular degeneration.
The compound has sparked interest for its ability to disrupt the blood vessels that form within a tumor ? and is designed to improve on anti-angiogenic therapies, which prevent new blood vessels from growing.
Susan Hager, director of corporate communications for OxiGene, noted that consumers are much more educated about their health than ever before.
"It's really important for people to know who we are," she said, adding that the media relations effort would "build additional validation around the science and better communicate how our compounds work."
The drug company had previously relied on IR firms to handle outreach.
But IR will still remain a significant focus for Wagged; the company is currently seeking to raise $75 million and perhaps attract new partners.
Jenny Moede, SVP of bioscience and healthcare at Wagged, noted that the company has already been "generating good coverage" that has created enthusiasm for the new drug category.
"They have incredible things happening in the clinic, but they do need to make money," she said. "They look to us to really get the most out of their clinical and regulatory milestones."
Terms were not disclosed.